ResMed (RMD) Q4 2012 Earnings Call August 02, 2012 4:30 pm ET Executives Peter C. Farrell - Founder, Executive Chairman, Chief Executive Officer and President Brett A. Sandercock - Chief Financial Officer and Principal Accounting Officer Michael J. Farrell - President of Americas Operations Donald Darkin - President of SDB Strategic Business Unit David Pendarvis - Chief Administrative Officer, Global General Counsel and Secretary Geoff Neilson - President of Respiratory Care Strategic Business Unit Robert Douglas - Chief Operating Officer Analysts Dan Hurren - UBS Investment Bank, Research Division Jacob Messina Michael Matson - Mizuho Securities USA Inc., Research Division Ben Andrew - William Blair & Company L.L.C., Research Division Ian Abbott - Goldman Sachs Group Inc., Research Division Nicholas Cameron - Deutsche Bank AG, Research Division Anthony Petrone - Jefferies & Company, Inc., Research Division David Stanton - Nomura Securities Co. Ltd., Research Division Matthew Prior - BofA Merrill Lynch, Research Division Saul Hadassin - Crédit Suisse AG, Research Division PresentationOperator
Good afternoon, ladies and gentlemen. Welcome to the Fourth Quarter 2012 ResMed, Inc. Earnings Conference Call. My name is Chris, and I will be your conference moderator for today. [Operator Instructions] The company has asked me to address certain matters: First, ResMed does not authorize the recording of any portion of this conference for any purpose. Second, during the conference call, ResMed may make forward-looking statements, such as projections of future revenue earnings, new product development or new markets for the company's products. These statements are made under the Safe Harbor Provision of the Private Securities Litigation Reform Act of 1995.